Table 1 Baseline characteristics of patients

Male, n (%)

Mean age, years (SD)

Height, cm (SD)

Weight, kg (SD)

Body Mass Index, kg/m² (SD)

Men with waist ≥ 102 cm, n (%)

Women with waist ≥ 88 cm, n (%)

Mean systolic blood pressure, mmHg (SD)^a

Mean diastolic blood pressure, mmHg (SD)^a

Heart rate, beats/min (SD)

Total cholesterol, mmol/l (SD)

HDL, mmol/L (SD)

LDL, mmol/L (SD)

Triglyceride, mmol/L (SD)

Creatininemia μmol/L (SD)

MDRD-estimated glomerular filtration rate, ml/min (SD)

Fasting glycemia, mmol/l (SD)

Left ventricular hypertrophy, n (%)

Family history of early cardiovascular event, n (%)

Albuminuria ≥ 20 mg/L, n (%)

Mean years since diagnosis of hypertension (SD)

Smoker status

  Current n (%)

  Past smoker < three years n (%)

  Non-smoker n (%)

Number of antihypertensive drugs, n (SD)

Type-2 diabetes, n (%)

Mean years since diagnosis of type-2 diabetes, (SD)

HbA1c, % (SD)

Cardiovascular risk factors, n (%)

Men > 50 or women > 60 years old

Current smoker or past smoker < three years

LDL ≥ 4.14 mmol/L or treatment

HDL ≤ 1.04 mmol/L

Number of cardiovascular risk factors, n (%)

  ≤ 2

  3

  4

  ≥ 5

Ten-year Framingham-Anderson risk score, (%)

Achieved all therapeutic targets (3 or 5), n/N (%)^a

Achieved blood pressure target, n (%)^a

Achieved LDL target, n (%)

No smoking, n (%)

Patients with diabetes

Achieved HbA1c target n/N (%)

Low-dose aspirin (yes) n/N (%)^a